How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

130,448 results for

Demulen 1/35

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Comparing diabetic outcomes in patients with T2DM and BMI 30-35 undergoing bariatric surgery vs. medical management: a systematic review and meta-analysis

Comparing diabetic outcomes in patients with T2DM and BMI 30-35 undergoing bariatric surgery vs. medical management: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith (...) based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination

2019 PROSPERO

162. Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months

before adding more. Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03020628 Recruitment Status : Completed First Posted : January 13, 2017 Last Update Posted : November 1, 2017 Sponsor: SK Chemicals Co., Ltd (...) this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 6 Months to 35 Months (Child) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Children aged 6 months to 35 months Those who was born after normal pregnancy period(37 weeks) for aged 6 months to < 1 year Those whose legally acceptable representative have given written

2017 Clinical Trials

163. Study on Prevention, Treatment and Mechanism of Preterm Labor for Chinese Pregnant Women ≥35 Years Old

for Chinese Pregnant Women ≥35 Years Old Actual Study Start Date : August 1, 2017 Estimated Primary Completion Date : June 30, 2020 Estimated Study Completion Date : December 30, 2020 Groups and Cohorts Go to Group/Cohort Intervention/treatment Study group Pregnant women ≥35 years old would have spontaneous preterm labor. There's no intervention in this group, because it's an Observational Study Model. Other: Observational Study Model There is no intervention for the study. Control group Pregnant women (...) ≥35 years old would not have spontaneous preterm labor. There's no intervention in this group, because it's an Observational Study Model. Other: Observational Study Model There is no intervention for the study. Outcome Measures Go to Primary Outcome Measures : Morbidity of Preterm birth [ Time Frame: 1 years ] Preterm delivery (PTD) is one of the most common and most serious complications of pregnancy. In China, preterm delivery is defined as delivery after 28 weeks completed but before 37 weeks

2017 Clinical Trials

164. Share 35 Changes Center Level Liver Acceptance Practices. (Full text)

Share 35 Changes Center Level Liver Acceptance Practices. Share 35 was implemented to provide improved access to organs for patients with Model for End-Stage Liver Disease (MELD) scores ≥ 35. However, little is known about the impact of Share 35 on organ offer acceptance rates. We evaluated all liver offers to adult patients who were ultimately transplanted between January 1, 2011 and December 31, 2015. The analyses focused on patients ranked in the top 5 positions of a given match run and used (...) multilevel mixed-effects models, clustering on individual wait-list candidate and transplant center. There was a significant interaction between Share 35 era and MELD category (P < 0.001). Comparing offers to MELD score ≥ 35 patients, offers after Share 35 were 36% less likely to be accepted compared with offers to MELD score ≥ 35 patients before Share 35 (adjusted odds ratio, 0.64). There was no clinically meaningful difference in the donor risk index of livers that were declined for patients

2017 Liver Transplantation PubMed abstract

165. Safety and Immunogenicity of Adenovirus 35 TB Vaccine Candidate in Adults with Active or Previous TB: a Randomized Trial. (Abstract)

Safety and Immunogenicity of Adenovirus 35 TB Vaccine Candidate in Adults with Active or Previous TB: a Randomized Trial. Administration of tuberculosis (TB) vaccines in participants with previous or current pulmonary TB may have the potential for causing harmful postvaccination immunologic (Koch-type) reactions.To assess the safety and immunogenicity of three dose levels of the AERAS-402 live, replication-deficient adenovirus 35-vectored TB candidate vaccine, containing three mycobacterial (...) antigens, in individuals with current or previous pulmonary TB.We performed a phase II randomized, placebo-controlled, double-blinded dose-escalation study in an HIV-negative adult South African cohort (n = 72) with active pulmonary TB (on treatment for 1-4 mo) or pulmonary TB treated at least 12 months before study entry and considered cured. Safety endpoints included clinical assessment, flow volume curves, diffusing capacity of the lung for carbon monoxide, pulse oximetry, chest radiograph, and high

2017 American Journal of Respiratory and Critical Care Medicine Controlled trial quality: uncertain

166. Methionine 35-sulfoxide reduces toxicity of aβ in red blood cell. (Abstract)

Methionine 35-sulfoxide reduces toxicity of aβ in red blood cell. The oxidation of methionine residue in position 35 of Ab to sulphoxide (Ab-sulphoxide) has the ability to deeply modify wild-type Ab 1-42 (Ab) neurotoxic action. Our previous studies suggest that in nucleated cells, lower toxicity of Ab-sulphoxide might result not from structural alteration, but from elevation of methionine sulphoxide reductase A (MsrA) activity and mRNA levels.On this basis, we hypothesised that red blood cell (...) (RBC), a cell devoid almost completely of MsrA activity, shares with nucleated cells an antioxidant system induced by methionine 35 sulphoxide, responsible for the lower toxicity of Ab-sulphoxide in RBC. (Results) Supporting this hypothesis, we found that the low toxicity of Ab-sulphoxide in RBC correlated with pentose phosphate pathway (PPP) flux increase, and this event was associated with a low level of methionine oxidation in total proteins. None of these effects were observed when cells were

2017 European journal of clinical investigation

167. 35-Year Experience with Surgical Treatment of Hidradenitis Suppurativa. (Abstract)

35-Year Experience with Surgical Treatment of Hidradenitis Suppurativa. Hidradenitis suppurativa is a painful and disfiguring chronic inflammatory condition affecting both men and women. Medical treatments, such as antibiotics and immunosuppressive agents, are often ineffective. Over time, patients can suffer from recurrent abscesses, chronic purulent drainage, scarring, and contractures that can only be corrected by surgical excision. There is no agreement, however, on the best way (...) for the surgeon to manage this condition. The purpose of this review is to describe the results of surgical treatment of this condition in a large cohort of patients managed by local excision of hidradenitis, healing by secondary intention and reoperation as needed.A retrospective review was conducted of all patients operated on by the author for hidradenitis over a 35-year period. Specific data abstracted included patient age, weight, admission, length of stay, wound size, type of wound care, number of post

2017 World Journal of Surgery

168. Peri-operative management of high-risk paediatric adenotonsillectomy patients: A survey of 35 UK tertiary referral centres. (Abstract)

Peri-operative management of high-risk paediatric adenotonsillectomy patients: A survey of 35 UK tertiary referral centres. Peri-operative management of high-risk paediatric patients undergoing adenotonsillectomy for treatment of obstructive sleep apnoea varies between tertiary referral hospitals. 'Day of surgery cancellation' (DoSC) rates of up to 11% have been reported due to pre-booked critical care being unavailable on the day of surgery as a result of competing needs from other hospital (...) departments. We report the results of a survey of peri-operative management in UK tertiary care centres of high-risk paediatric patients undergoing adenotonsillectomy for obstructive sleep apnoea (OSA).An 8-point questionnaire was developed using a cloud-based software platform (www.surveymonkey.com). A web-link to the survey was embedded in a customised e-mail which was sent via secure server to the Clinical Leads for Paediatric Otolaryngology at 35 United Kingdom (UK) Tertiary referral centres.The

2017 International Journal of Pediatric Otorhinolaryngology

169. Improved Post-Transplant Mortality After Share 35 for Liver Transplantation. (Full text)

for Organ Sharing database. All adult deceased donor LTs from January 1, 2010, to March 31, 2016, were included in the analysis. One-year patient survival before and after Share 35 was assessed by multivariable Cox proportional hazards analysis, with adjustment for variables known to affect graft survival. Of 34,975 adult LT recipients, 16,472 (47.1%) were transplanted after the implementation of Share 35, of whom 4,599 (27.9%) had a Model for End-Stage Liver Disease (MELD) score ≥35. One-year patient (...) survival improved from 83.9% to 88.4% after Share 35 (P < 0.01) for patients with MELD ≥35. There was no significant impact on survival of patients with MELD <35 (P = 0.69). Quality of donor organs, as measured by a donor risk index without the regional share component, improved for patients with MELD ≥35 (P < 0.01) and worsened for patients with lower MELD (P < 0.01). In multivariable Cox regression analysis, Share 35 was associated with improved 1-year patient survival (hazard ratio, 0.69; 95

2017 Hepatology PubMed abstract

170. Hearing Threshold Shifts Among 11- to 35-Year-Olds With Early Hearing Impairment. (Abstract)

Hearing Threshold Shifts Among 11- to 35-Year-Olds With Early Hearing Impairment. Data obtained from the clinical records of selected 11- to 35-year-olds with preadult onset hearing impairment were analyzed with 2 primary aims: (1) to determine the incidence of hearing threshold level (HTL) shift in this cohort and, (2) to examine the relationship between HTL shift, whole-of-life noise exposure, and other factors.Cross-sectional cohort study. Retrospective HTL + survey data for a sample of 237

2017 Ear and hearing

171. Emtricitabine/rilpivirine/tenofovir alafenamide (Odefsey) - human immunodeficiency virus-1 (HIV-1)

Medicines Strategy Group. Final Appraisal Recommendation – 3316: Emtricitabine/rilpivirine/tenofovir alafenamide (Odefsey ® ) 200 mg/25 mg/25 mg film-coated tablets. November 2016. Recommendation of AWMSG Emtricitabine/rilpivirine/tenofovir alafenamide (Odefsey ® ) is recommended as an option for use within NHS Wales for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) without known mutations associated (...) Emtricitabine/rilpivirine/tenofovir alafenamide (Odefsey) - human immunodeficiency virus-1 (HIV-1) Final Appraisal Recommendation Advice No: 3316 – November 2016 Emtricitabine/rilpivirine/tenofovir alafenamide (Odefsey ® ) 200 mg/25 mg/25 mg film-coated tablets Limited submission by Gilead Sciences Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3031), which includes the AWMSG Secretariat

2016 All Wales Medicines Strategy Group

172. Emtricitabine/tenofovir alafenamide (Descovy) - human immunodeficiency virus type 1 (HIV 1)

12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1). (...) Emtricitabine/tenofovir alafenamide (Descovy) - human immunodeficiency virus type 1 (HIV 1) Final Appraisal Recommendation Advice No: 2716 – September 2016 Emtricitabine/tenofovir alafenamide (Descovy ® ? ) 200 mg/10 mg, 200 mg/25 mg film-coated tablets Limited submission by Gilead Sciences Ltd Additional note: • Please refer to the Summary of Product Characteristics for the full licensed indication. In reaching the above recommendation AWMSG has taken account of the appraisal documentation

2016 All Wales Medicines Strategy Group

173. Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya) - human immunodeficiency virus 1 (HIV 1)

as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2216: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya ®? ) 150 mg/150 mg/200 mg/10 mg tablets. July 2016. Recommendation of AWMSG Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya ® ? ) is recommended as an option for use within NHS Wales for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV-1 (...) Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya) - human immunodeficiency virus 1 (HIV 1) Final Appraisal Recommendation Advice No: 2216 – July 2016 Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya ® ? ) 150 mg/150 mg/200 mg/10 mg tablets Limited submission by Gilead Sciences Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2248), which includes the AWMSG

2016 All Wales Medicines Strategy Group

174. Flash Glucose Monitoring System for People with Type 1 or Type 2 Diabetes

rate of 15%, to $38.6 million ($7.7 million for type 1 diabetes and $30.9 million for type 2 diabetes) in year 5, at an uptake rate of 35%. In this analysis, we assumed that people with type 1 diabetes who self-monitor their blood glucose levels would perform six blood glucose tests daily and that people with type 2 diabetes would perform four blood glucose tests daily. For people switching from self-monitoring of blood glucose using the maximum number of blood glucose test strips for reimbursement (...) Appraisal of Evidence 15 Results 15 Literature Search 15 Type 1 Diabetes 19 Type 2 Diabetes 25 Combined Type 1 and Type 2 Diabetes 29 Discussion 30 Limitations 31 Ongoing Studies 31 Conclusions 31 ECONOMIC EVIDENCE 33 Research Questions 33 Methods 33 Economic Literature Search 33 Literature Screening 33 Inclusion Criteria 33 Exclusion Criteria 33 Outcomes of Interest 33 Data Extraction 34 Study Applicability 34 Results 35 December 2019 Ontario Health Technology Assessment Series; Vol. 19: No. 8, pp. 1

2019 Health Quality Ontario

175. Does the Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Improve Survival in Septic Adults? (Full text)

/kg 7 3,607 4,411 8,676 11,251 Serial lactate measurements and fluid infusion of 30 mL/kg 4 6,208 7,099 5,632 6,752 Assessing fluid responsiveness 3 99 109 102 111 Assessing SEP-1 1 94 110 35 48 After screening of 56,563 references, 18 reports representing 20 studies met inclusion criteria and compared survival in septic patients receiving one or more of the SEP-1 interventions versus a control group. Meta-analysis was not performed because of the large heterogeneity between included studies (...) Does the Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Improve Survival in Septic Adults? Does the Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Improve Survival in Septic Adults? - Annals of Emergency Medicine Email/Username: Password: Remember me Search Terms Search within Search Share this page Access provided by Volume 73, Issue 4, Pages 363–365 Does the Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Improve Survival in Septic Adults? x

2019 Annals of Emergency Medicine Systematic Review Snapshots PubMed abstract

176. Adult liver transplantation: A UK clinical guideline – part 1: pre-operation

/. ORCiD iD Charles Millson http:// orcid. org/ 0000- 0001- 6989- 9497 ReFeRen Ces 1 Calne RY. Transplantation of the liver. Ann Surg 1978;188:129–38. 2 Neuberger J. Liver transplantation in the United Kingdom. Liver T ranspl 2016;22:1129–35. 3 NHS Blood and Transplant. Annual report on liver transplantation 2015/2016. 4 Devlin J, O'Grady J. Indications for referral and assessment in adultliver transplantation: a clinical guideline. Gut 1999;45:vi1–22. 5 BASL. Guidelines on referral for liver (...) Adult liver transplantation: A UK clinical guideline – part 1: pre-operation 1 Millson C, et al. Frontline Gastroenterology 2020;0:1–10. doi:10.1136/flgastro-2019-101215 Review Adult liver transplantation: A UK clinical guideline - part 1: pre- operation Charles Millson , 1 Aisling Considine, 2 Matthew E Cramp, 3 Andrew Holt, 4 Stefan Hubscher, 5 John Hutchinson, 6 Kate Jones, 7 Joanna Leithead, 8 Steven Masson, 9 Krish Menon, 10 Darius Mirza, 11 James Neuberger, 12 Raj Prasad, 13 Anthony Pratt

2020 British Society of Gastroenterology

177. Di­chlorido­[6,8,22,24,34,36-hexa­methyl-33,35-diaza-3,11,19,27-tetra­azonia­penta­cyclo[27.3.1.15,9.113,17.121,25]hexa­triaconta-1(33),5,7,9(34),13,15,17(35),21,23,25(36),29,31-dodeca­ene-κ6 N 3,N 11,N 19,N 27,N 33,N 35]dipalladium(II) bis(per­ (Full text)

Di­chlorido­[6,8,22,24,34,36-hexa­methyl-33,35-diaza-3,11,19,27-tetra­azonia­penta­cyclo[27.3.1.15,9.113,17.121,25]hexa­triaconta-1(33),5,7,9(34),13,15,17(35),21,23,25(36),29,31-dodeca­ene-κ6 N 3,N 11,N 19,N 27,N 33,N 35]dipalladium(II) bis(per­ In the crystal structure of the title compound, [Pd2(C36H42N6)Cl2](ClO4)2·2C3H7NO·2CH3OH, the dinuclear Pd(II) complex cation lies on an inversion center. Each Pd(II) ion has a distorted square-planar coordination sphere, defined by three N

2013 Acta Crystallographica Section E: Structure Reports Online PubMed abstract

178. Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil (HIV-1 in adolescents) ? Benefit assessment according to §35a Social Code Book (SGB) V

was based on a dossier compiled by the pharmaceutical company (hereinafter referred to as “the company”). The dossier was sent to IQWiG on 16 November 2017. Research question The aim of the present report was to assess the added benefit of EVG/COBI/FTC/TDF in comparison with the appropriate comparator therapy (ACT) in adolescents aged 12 to < 18 years with a body weight of = 35 kg who are infected with human immunodeficiency virus type 1 (HIV-1) without known mutations involving resistances against 1 (...) of the 3 antiretroviral (ARV) drugs and the occurrence of toxicities that rule out the application of other treatment regimens which do not contain tenofovir disoproxil (fumarate) (TDF). Table 2: Research questions of the benefit assessment of EGV/COBI/FTC/TDF Research question Subindication ACT a 1 Treatment of HIV-1 infection in adolescents aged 12 to < 18 years with a body weight of = 35 kg who are infected with HIV-1 without known mutations involving resistances against 1 of the 3 ARV drugs

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

179. Excess mortality and life expectancy of individuals with type 1 diabetes: a rapid review

COMPLICATIONS 34 KCE Report 314 Excess mortality and life expectancy of individuals with type 1 diabetes 3 4.7. MICRO-VASCULAR COMPLICATIONS 35 4.8. MACRO-VASCULAR COMPLICATIONS 35 4.9. NEPHROPATHY AS A PROGNOSTIC INDICATOR 35 4.10. CARDIAC AUTONOMIC NEUROPATHY 37 4.11. WELL KNOWN RISK FACTORS REQUIRING SPECIAL ATTENTION 37 4.12. SOCIO-ECONOMIC STATUS 38 4.13. SPECIFIC FEATURES OF LONG SURVIVING PATIENTS WITH T1D 38 4.14. SECULAR TRENDS 39 4.15. CONCLUSION 39 5. SYNTHESIS 41 5.1. INTRODUCTION 41 5.2 (...) , myocardial infarction). 66-68 KCE Report 314 Excess mortality and life expectancy of individuals with type 1 diabetes 35 Severe diabetic ketoacidosis (DKA) can be life-threatening and arises when there is no insulin in the body or when it is below a critical level. T1D patients rely on insulin for survival. Insulin is necessary among others for the inhibition of lipolysis. When insulin levels are critically low or when insulin is absent lipolysis will no longer be inhibited, a situation that will lead

2019 Belgian Health Care Knowledge Centre

180. Diagnostic testing for ROS proto-oncogene 1 (ROS1) rearrangements in non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment

108 nCounter Prep Station™ and Digital Analyzer™ ZytoLight SPEC ROS1 probe 27/79 (35%) 70% 96% FISH = fluorescent in-situ hybridisation; IHC = immunohistochemistry; NGS = next-generation sequencing; NPV = negative predictive value; pos = positive; PCR = polymerase chain reaction; PPV = positive predictive value; RNA = ribonucleic acid; ROS1 = ROS proto- oncogene 1; RT-PCR = reverse transcription polymerase chain reaction. a May be higher than the denominator in the results due to failed tests (...) Diagnostic testing for ROS proto-oncogene 1 (ROS1) rearrangements in non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment 1 Public Summary Document Application No. 1454- Diagnostic testing for ROS proto-oncogene1 (ROS1) rearrangements in patients with non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment Applicant: Pfizer Australia Pty Ltd Date of MSAC consideration: MSAC 73 rd Meeting, 26-27 July 2018 MSAC 71 st Meeting, 23

2018 Medical Services Advisory Committee

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>